Clinical Trials

Are you an adult with atrial fibrillation? In this study, researchers are comparing a continuous direct oral anticoagulation (DOAC) use versus time-limited (1 month) DOAC guided by an AF-sensing Smart Watch (AFSW) for persons with atrial fibrillation and a moderate risk of stroke. Participants must be between the ages of 22 and 85 and have a history of atrial fibrillation. The study is taking place at locations in California, Colorado, Florida, Georgia, Illinois, Indiana, Iowa, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, New Jersey, New Mexico, New York, North Carolina, Ohio, Oklahoma, Pennsylvania, South Carolina, Texas, Virginia, Wisconsin, and Washington, D.C.

Did you develop atrial fibrillation after coronary artery bypass graft (CABG) surgery? Did you develop atrial fibrillation after a coronary artery bypass grafting (CABG) surgery? This study is looking at how well oral anticoagulation medicines work to prevent complications, such as blood clots and heart attack, for patients who experience post-operative atrial fibrillation (POAF). This study is in multiple locations around the country.

The Bashir™ Endovascular Catheter has been designed to administer therapeutic agents in the peripheral vasculature. Because of the unique design of the catheter, with its six expandable infusion limbs, the Bashir™ Endovascular Catheter has the ability to: 1. Create a much larger central channel for blood flow, thereby utilizing the body's own endogenous fibrinolytic agents to lyse the clot, and 2. Greatly enhance the radial dispersion of a catheter-administered thrombolytic agent throughout the thrombus. Expansion of the multiple arms of the basket in the infusion catheter causes fissuring of the clot. The net result is that a greater surface area of clot is exposed to both endogenous and exogenously administered lytic agents, thereby promoting clot dissolution.

This study is evaluating the dynamics of red blood cell lysis, pfH, protective proteins and organ injury, limits will be set for safe levels of pfH following the use of CPB.

Are you a healthy adult between the ages of 18 and 60? For this study, researchers are testing a new medication to treat a lung injury called pulmonary arterial hypertension. First, researchers will test the medication to see how it affects healthy people. To participate, you must be a healthy adult between the ages of 18 and 60. The study will take place at the National Institutes of Health Clinical Center in Bethesda, Maryland.

The investigators' central hypothesis is that early combination therapy with two PAH-specific oral therapies that have been shown to be well tolerated in the pediatric population, sildenafil and bosentan, will result in better World Health Organization (WHO) functional class at 12 months after initiation of PAH treatment than therapy with sildenafil alone.

Has your doctor recommended right heart cardiac catheterization for you? This study is investigating new magnetic resonance imaging (MRI) techniques that use a guidewire to help position a heart catheter within the heart. MRI fluoroscopy shows pictures of the heart so that doctors can watch while they work. Using the guidewire during MRI may improve the procedure of heart catheterization. To participate in this study, you must be at least 18 years old, and your doctor must have recommended right heart catheterization for you. This study is located in Bethesda, Maryland.

Are you an adult interested in a new treatment for pulmonary hypertension? This study is exploring whether a medicine called spironolactone can improve heart and lung function during exercise in people who have pulmonary hypertension. To participate in this study, you must be 18 to 99 years old and have a type of pulmonary hypertension known as pulmonary arterial hypertension. This study is located in Bethesda, Maryland.

Este estudio explora si un medicamento llamado espironolactona puede mejorar la función cardíaca y pulmonar durante el ejercicio en personas con hipertensión pulmonar. Para participar en este estudio, debe tener entre 18 y 99 años y un tipo de hipertensión pulmonar conocido como hipertensión arterial pulmonar. Este estudio se lleva a cabo en Bethesda (Maryland).